Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04887506 · ClinicalTrials.gov registry record · Phase 3
TAVT-45 (Abiraterone Acetate) Granules in Patients With Prostate Cancer
A Phase 3 study of Metastatic Castration-Resistant Prostate Cancer and Metastatic Prostate Cancer, sponsored by Tavanta Therapeutics.
- Completed
- Registry status
- Phase 3
- Development phase
- 107
- Enrollment target
- 20
- Study locations
NCT04887506: Completed Phase 3 study of Metastatic Castration-Resistant Prostate Cancer and Metastatic Prostate Cancer, sponsored by Tavanta Therapeutics.
NCT04887506 is a Phase 3 study of Metastatic Castration-Resistant Prostate Cancer and Metastatic Prostate Cancer that has completed, run by Tavanta Therapeutics. The registered enrollment target is 107 participants, below the 196-participant average among 69 other Metastatic Castration-Resistant Prostate Cancer trials with a reported enrollment target (45% lower). The trial reports 20 study locations across 15 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04887506, a Phase 3 study of Metastatic Castration-Resistant Prostate Cancer and Metastatic Prostate Cancer, has completed, sponsored by Tavanta Therapeutics.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 107 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to investigate the safety and efficacy of a new formulation of an existing drug product called TAVT-45 in patients with metastatic prostate cancer.
Primary Outcome
The primary endpoint was the between group comparison of serum testosterone levels for the average of levels on Days 9 and 10 (rounded-up) for mCRPC patients.
Conditions Studied
Interventions
- DRUG Prednisone
- DRUG TAVT-45
- DRUG Zytiga
Study Locations (20)
Other
- Research Site - Brest
- Research Site - Budapest
- Research Site - Budapest
- Research Site - Debrecen
- Research Site - Bydgoszcz
California
- Research Site - Los Angeles
- Research Site - San Bernardino
Alabama
- Research Site - Homewood
Arizona
- Research Site - Tucson
Arkansas
- Research Site - Little Rock
Colorado
- Research Site - Denver
Florida
- Research Site - Bradenton
Idaho
- Research Site - Meridian
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 107 participants |
| Start Date | 2021-05-05 |
| Est. Completion | 2022-10-20 |
| Phase | Phase 3 |
What the finished NCT04887506 record still lists
NCT04887506 is an interventional study that assigns participants to a tested intervention. The registered 107 participants enrollment target is mid-sized for trials with a published cap, below the 196-participant average among 69 other Metastatic Castration-Resistant Prostate Cancer trials with a reported enrollment target (45% lower).
The record links to 3 conditions, with Metastatic Castration-Resistant Prostate Cancer appearing as the primary indexed condition, and to 3 interventions - of which Prednisone is the first listed.
NCT04887506 names 20 study sites across 15 states, led by Other, California, Alabama.
Frequently Asked Questions
What is clinical trial NCT04887506 about?
NCT04887506 is a clinical study titled "TAVT-45 (Abiraterone Acetate) Granules in Patients With Prostate Cancer". The purpose of this study is to investigate the safety and efficacy of a new formulation of an existing drug product called TAVT-45 in patients with metastatic prostate cancer.
What is the current status of trial NCT04887506?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 107 participants. The study started on 2021-05-05. Estimated completion is 2022-10-20.
What conditions does trial NCT04887506 study?
This clinical trial studies the following conditions: Metastatic Castration-Resistant Prostate Cancer, Metastatic Prostate Cancer, Metastatic Castration-Sensitive Prostate Cancer.
What interventions are being tested in trial NCT04887506?
The interventions under investigation include: Prednisone (DRUG), TAVT-45 (DRUG), Zytiga (DRUG).
Who is sponsoring clinical trial NCT04887506?
This trial is sponsored by Tavanta Therapeutics, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04887506 being conducted?
This trial has 20 study locations across Alabama, Arizona, Arkansas, California, Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Metastatic Castration-Resistant Prostate Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04887506's enrollment target sits among peer trials
107 26th of 69 higher than 44 of 69 other Metastatic Castration-Resistant Prostate Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Metastatic Castration-Resistant Prostate Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Learn How PF-06821497 (Mevrometostat) Works in Men With Metastatic Castration-resistant Prostate Cancer.
RECRUITING · Phase 3
-
The Study of 177Lu-TLX591 Plus SOC Versus SOC Alone in Patients With mCRPC (ProstACT Global)
RECRUITING · Phase 3
-
A Study to Compare the Efficacy and Safety of BMS-986365 Versus the Investigator's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer
RECRUITING · Phase 3
-
A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer
RECRUITING · Phase 3
-
Phase 3 Study of Xaluritamig vs Cabazitaxel or Second Androgen Receptor-Directed Therapy in Participants With Progressive Metastatic Castration-Resistant Prostate Cancer (XALute)
RECRUITING · Phase 3
-
Study Evaluating mCRPC Treatment Using PSMA [Lu-177]-PNT2002 Therapy After Second-line Hormonal Treatment
ACTIVE NOT RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05491668 · 107 participants
Physiological Assessment of Severe Coronary Stenosis for Informing Planned PCI
- NCT06041594 · 107 participants · NA
Treating Pulmonary Embolism With Laguna Thrombectomy System (TRUST)
- NCT06081426 · 107 participants · NA
Examining Neurobiological Mechanisms Underlying the Therapeutic Effect of the Ketogenic Diet in Bipolar Disorder (BD)
- NCT06527599 · 107 participants · NA
Screening in Trauma for Opioid Misuse Prevention - an Adaptive Intervention
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI